Natalizumab and PML: a risky business?
Clifford
David B
DB
Department of Neurology, Box 8111, 660 South Euclid Avenue, Saint Louis, MO 63110, USA. cliffordd@neuro.wustl.edu
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy; D006801:Humans; D007577:JC Virus; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000821:virology; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000188:drug therapy; D000069442:Natalizumab; D014766:Viremia / Q000821:virology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069442:Natalizumab